Results 61 to 70 of about 96,147 (290)

Multimodal Wearable Biosensing Meets Multidomain AI: A Pathway to Decentralized Healthcare

Advanced Science, EarlyView.
Multimodal biosensing meets multidomain AI. Wearable biosensors capture complementary biochemical and physiological signals, while cross‐device, population‐aware learning aligns noisy, heterogeneous streams. This Review distills key sensing modalities, fusion and calibration strategies, and privacy‐preserving deployment pathways that transform ...
Chenshu Liu, Haolin Fan, Minwoo Kim, Tong Zhou, Pinyi Yang, Lingdi Zhao, Yiran Wang, Ziyuan Che, Chia‐Wei Liu, Bingbing Li, Yangzhi Zhu   +10 more
wiley   +1 more source

Ambulatory blood pressure monitoring in clinical trials with antihypertensive agents [PDF]

, 1995
Ambulatory blood pressure monitoring (ABPM) is being used increasingly for the evaluation of antihypertensive agents in clinical trials. In this brief review several aspects of ABPM are discussed.
Meiracker, A.H. (Anton) van den
core   +1 more source

AI‐Assisted IoT‐Enabled ECG Monitoring: Integrating Foundational and Generative AI Tools for Sustainable Smart Healthcare—Recent Trends

AI &Innovation, EarlyView.
ABSTRACT The rapid evolution of the Internet of Things (IoT) has significantly advanced the field of electrocardiogram (ECG) monitoring, enabling real‐time, remote, and patient‐centric cardiac care. This paper presents a comprehensive survey of AI assisted IoT‐based ECG monitoring systems, focusing on the integration of emerging technologies such as ...
Amrita Choudhury, Kandarpa Kumar Sarma, Lachit Dutta   +2 more
wiley   +1 more source

EFFECT OF CANDESARTAN ON PARAMETERS OFDAILYBLOOD PRESSURE IN PATIENTS WITH CHRONIC KIDNEYDISEASE ON HEMODIALYSIS

Український Журнал Нефрології та Діалізу, 2017
Introduce.Advances of normal blood pressure in patients on program hemodialysis presented a serious problem related disciplines. For verification hypertension used routine blood pressure measurement and ambulatory monitoring to control the pressure in ...
V. A. Vizir, О. G. Ovska, A. S. Sadomov
doaj   +1 more source

What is the best way to identify patients with white-coat hypertension? [PDF]

, 2005
Ambulatory blood pressure monitoring is currently the gold standard for detecting patients with white-coat hypertension. Women and all patients with lower office systolic blood pressures, stage I hypertension, and no target organ damage are more likely ...
Blackwell, Jean, Fisher, Michael
core  

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

British Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić, Yusuf Ziya Sener, Marijana Vučković, Joseph Edgar Blais, Almir Fajkić, Emina Sher, Mislav Radić, Josipa Radić   +7 more
wiley   +1 more source

Role of renin–angiotensin aldosterone system on short-term blood pressure variability in hypertensive patients

Clinical and Experimental Hypertension, 2018
The relationship between the renin–angiotensin aldosterone system and short-term blood pressure variability has not been well elucidated. Here, we investigated whether blood pressure variability determined by ambulatory blood pressure monitoring differed
Minako Inoue, Kiyoshi Matsumura, Yoshie Haga, Yasuo Kansui, Kenichi Goto, Toshio Ohtsubo, Takanari Kitazono   +6 more
doaj   +1 more source

Analysis of short-term blood pressure variability in pheochromocytoma/paraganglioma patients [PDF]

, 2019
Data on short-term blood pressure variability (BPV), which is a well-established cardiovascular prognostic tool, in pheochromocytoma and paraganglioma (PPGL) patients is still lack and conflicting.
Bisogni, V., Bonvicini, M., Celi, M., Ciardi, A., Concistre, A., De Toma, G., Iannucci, G., Letizia, C., Mezzadri, M., Oliviero, G., Olmati, F., Petramala, L., Saracino, V., Tonnarini, G., Torre, G. L.   +14 more
core   +1 more source

Intravenous lanadelumab for the treatment of moderately ill COVID‐19 patients

British Journal of Clinical Pharmacology, EarlyView.
Aims Kallikrein‐kinin system (KKS) dysregulation is hypothesized to play a pathogenetic role in COVID‐19‐associated pulmonary oedema. To investigate the efficacy and safety of intravenous lanadelumab, a monoclonal antibody that inhibits plasma kallikrein, in COVID‐19, we conducted a phase 2, open‐label, randomized‐controlled, proof‐of‐concept ...
Job J. Engel, Christine van Linge, W. Joost Wiersinga, Ilse J. E. Kouijzer, Quirijn de Mast, Robert‐Jan Hassing, Danique J. H. Huijbens, Helen L. Leavis, Roger Schutgens, Coen Maas, Kit C. B. Roes, Frank L. van de Veerdonk, Roger Brüggemann   +12 more
wiley   +1 more source

The evolving therapeutic landscape of spinal muscular atrophy – A scoping review of investigational agents, emerging delivery technologies and strategic innovations

British Journal of Clinical Pharmacology, EarlyView.
Spinal muscular atrophy (SMA) is a severe neuromuscular disease with emerging therapeutic complexity. This review aims to systematically map the global pipeline of investigational treatments for SMA. Using ClinicalTrials.gov and complementary international registries, we identified 21 planned or ongoing interventional trials from 2020 to 2025 targeting
Andrej Belančić, Patrick Eustaquio, Elvira Meni Maria Gkrinia, Ivana Stević, Eugen Javor, Yun Wah Lam, Slobodan Janković, Dinko Vitezić   +7 more
wiley   +1 more source